摘要
类风湿关节炎(RA)是一种以对称性多关节炎为主要临床表现的自身免疫性疾病。生物制剂用于治疗RA具有一定疗效,近年来阿达木单抗临床研究获得一定进展,其停药和减量的相关报道也引起广泛关注。本文综述近年来阿达木单抗治疗RA的研究进展,及其停药和减量的报道,并简要概述其安全性。
Rheumatoid arthritis(RA) is an autoimmune disease characterized by symmetric poly arthritis as the main clinical manifestation. The biological agents in RA treatment have a certain effect. Recently, the clinical studies of adalimumab obtain much progresses, especially the drug withdrawal and reduction has been attended. This review describes the recent advances of adalimumab in RA treatment, and a brief overview of its safety.
作者
王霞
夏光涛
WANG Xia;XIA Guang-tao(Department of Rheumatology and Immunology, Shandong Provincial Hospital, Shandong University, Ji'nan 250021, China)
出处
《世界临床药物》
CAS
2018年第4期280-284,共5页
World Clinical Drug
基金
山东省自然科学基金(编号:ZR2015HM082)